Navigation Links
Abbott HIV Test Demonstrates Earlier Disease Detection
Date:7/22/2009

CHICAGO, July 22 /PRNewswire-FirstCall/ -- Research presented today at the American Association for Clinical Chemistry annual meeting shows that an assay developed by Abbott for simultaneous detection of both HIV antigens and antibodies reduced the detection window by zero to nine days in this study compared to HIV antibody-only assays. Earlier detection was shown on four of the five panels tested.

"The ability to use a blood test to diagnose HIV sooner, in the acute phase of the disease where antibodies are not yet present, presents an exciting opportunity in the fight against HIV," said Gerald Schochetman, Ph.D., senior director, infectious diseases, research and development, Abbott Diagnostics. "This data is very promising and we are excited about the clinical potential of this assay to help detect HIV earlier."

The Abbott ARCHITECT HIV Combo (Ag/Ab) assay is an automated immunoassay test designed to detect HIV p24 antigen and antibodies to HIV type 1 (HIV-1 Group M and Group O) and/or type 2 (HIV-2) in human serum and plasma. Unlike conventional HIV serology assays that only detect HIV antibodies, ARCHITECT HIV Combo (Ag/Ab) incorporates HIV p24 antigen detection which enables laboratories to diagnose HIV infection before HIV antibodies are detectable. HIV p24 antigen is a viral protein of the HIV antigen.

The assay was launched in Europe in 2004 and is not yet available in the United States. Abbott expects to submit a pre-market approval application for the ARCHITECT HIV Combo (Ag/Ab) assay to the U.S. Food and Drug Administration (FDA) later this year. Upon approval, Abbott's new ARCHITECT HIV Combo assay will continue Abbott's long history of leadership in HIV diagnostics. Abbott developed the first-ever test for HIV almost 25 years ago, in 1985.

About HIV

The Centers for Disease Control and Prevention (CDC) estimates that there are more than 35,000 new cases of HIV reported in the United States annually. In 2008, UNAIDS estimated that 2.7 million people throughout the world are newly infected with HIV each year. Leading risk factors for HIV infection include male-to-male sexual contact, high-risk heterosexual contact and intravenous drug use.

ARCHITECT HIV Combo (Ag/Ab) assay is not intended for use in blood screening, plasma or tissue donors. The effectiveness of ARCHITECT HIV Combo (Ag/Ab) for use in screening blood, plasma or tissue donors has not been established. The assay result does not distinguish between the detection of HIV p24 antigen, HIV-antibody, or HIV-2 antibody.

About Abbott's Diagnostics Businesses

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 69,000 customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs. The history of Abbott is filled with examples of first-of-a-kind diagnostic products and significant technological and research advancements.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

ARCHITECT is a trademark of Abbott Laboratories.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
2. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
3. Abbott Named One of the Top 10 Companies for Scientists
4. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
5. Abbott to Present at Barclays Global Healthcare Conference
6. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
7. Abbott Announces 11 Percent Increase in Quarterly Dividend
8. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
9. Abbott Announces Earnings Guidance for 2009
10. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
11. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):